Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release

Biophytis announces a € 10 million capital increase through private placement. Read the Press Release

Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release

Biophytis Reports H1 2020 Financial Results and Provides Business Update. Read the Press Release

Interview of Stanislas Veillet, CEO of Biophytis on the Grand Angle – TV5 Monde (in French). Watch the video

Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release

Biophytis recently attended the Digital ChinaBio conference taking place August 25-27, and will also attend the following conferences:

• The HC Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020 (Virtual Conference)
• The HTID (Health Tech Innovation Days): October 5^th & 6^th, Paris
• Bio Europe Fall : October 26-29^th (Virtual Conference)

Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia. Read the Press Release

Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure.  Read the Press Release

Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release

Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure. Read the Press Release

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA. Read the Press Release

Results of the Combined General Meeting of May 28, 2020: All ordinary and extraordinary resolutions have been adopted. Read the Press Release

Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders. Read the Press Release

Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release

Biophytis shares resume trading following the implementation of measures ordered in connection with a dispute with NEGMA. Read the Press Release

Convening of another combined General Meeting at a Later Date. Read the Press Release

Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release

Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders. Read the Press Release

Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA). Read the Press Release

Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders.  Read the Press Release

Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19. Read the Press Release

Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release

Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release

2019 Annual Financial Report made available. Read the Press Release

Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release

Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia. Read the Press Release

Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release

Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release

Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release

Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release

Biophytis shares trading is suspended pending a new press release. Read the Press Release

Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release

Interview of Stanislas Veillet, CEO of Biophytis by Didier Testot on the web Tv www.labourseetlavie.com (in French)

Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment. Read the Press Release

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release

Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release